ReviewDiscover oncology2025
The role of LncRNA SNHG3 in human cancers.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A new cuproptosis-associated lncRNA signature predicts the prognosis of clear cell renal cell carcinoma patients.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
An essential category of non-protein-coding RNA molecules, known as long noncoding RNAs (lncRNAs), are naturally occurring RNA sequences exceeding 200 nucleotides in length. Accumulating evidence has unveiled the significant involvement of lncRNAs in various cancers, where they are known to be a key factor for tumors' statement changing, e.g., modulating proliferative, apoptotic, migratory and chemotherapy resistance in cells. In addition, lncRNAs are also regarded as potential diagnostic and prognostic tumor biomarkers. Studies have suggested that lncRNAs modulate biological processes by regulating linear RNA transcription and protein production. A recently discovered long non-coding RNA, SNHG3, is identified to have associations with cancer, which displays atypical expression patterns and functions as an oncogene in various cancers. Additionally, SNHG3 has been demonstrated to hold promise as a diagnostic biomarker and a tool for prognostic assessment in cancer patients. This review summarizes current knowledge about SNHG3's expression, functional roles, molecular mechanisms, and implications for diagnosis and prognosis in human cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.